RTP Mobile Logo
Submitted by web@researchtop... on Tue, 05/28/2019 - 09:03
ERMBC19

Module 1 Biology of the CDK4/6 pathway and pharmacology of the CDK4/6 inhibitors abemaciclib, ribociclib and palbociclib

Track 1: Role of CDK4/6 in the cell cycle and in the development of breast cancer
Track 2: Mechanism of action of CDK4/6 inhibitors in patients with breast cancer
Track 3: Pharmacology, efficacy and tolerability of abemaciclib, ribociclib and palbociclib
Track 4: Continuous versus intermittent dosing of CDK4/6 inhibitors
Track 5: Perspective on optimal dose scheduling of CDK4/6 inhibitors
Track 6: Patient age and comorbidities and the use of CDK 4/6 inhibitors

Module 2 Management of ER-positive, HER2-negative metastatic breast cancer (mBC) in postmenopausal patients

Track 7: Available data with the 3 approved CDK4/6 inhibitors for postmenopausal patients
Track 8: Case (Dr Tolaney): A woman in her late 60s with de novo ER-positive, HER2-negative mBC receives abemaciclib and anastrozole as first-line therapy
Track 9: Prognosis and clinical care for patients with ER-positive, HER2-negative mBC
Track 10: Activity of palbociclib, abemaciclib and ribociclib
Track 11: Side-effect profile of CDK4/6 inhibitors

Module 3 Role of CDK4/6 inhibitors for premenopausal patients with ER-positive, HER2-negative mBC

Track 12: Overview of the role of endocrine therapy for premenopausal patients with ER-positive, HER2-negative mBC
Track 13: Unique biology of premenopausal breast cancer; role of ovarian suppression for patients with ER-positive mBC
Track 14: Rationale for the use of CDK4/6 inhibitors in ER-positive breast cancer
Track 15: Efficacy and tolerability of CDK4/6 inhibitors in premenopausal patients with ER-positive breast cancer
Track 16: Case (Dr Goel): A premenopausal woman in her mid-30s experiences rapid disease progression while receiving palbociclib with endocrine therapy for ER-positive, HER2-negative mBC
Track 17: Role of the 21-gene Recurrence Score® for patients with ER-positive, HER2-negative breast cancer in the neoadjuvant setting
Track 18: Management of ER-positive, HER2-negative mBC in premenopausal women
Track 19: Perspective on the potential use of CDK4/6 inhibitors for patients with ER-positive, HER2-negative breast cancer in the adjuvant setting
Track 20: PALOMA-3 study: Overall survival results with the addition of palbociclib to fulvestrant for ER-positive, HER2-negative advanced breast cancer
Track 21: Clinical implications of the results of the PALOMA-3 study
Track 22: Survival outcomes for patients with ESR1 mutations who received palbociclib and fulvestrant on the PALOMA-3 study
Track 23: Molecular profiling for patients with ER-positive, HER2-negative mBC and implications for clinical decision-making

Module 4 Site and extent of metastases, including CNS involvement, and outcomes with CDK4/6 inhibitors; predictors of response to therapy

Track 24: Time to response with CDK4/6 inhibitors
Track 25: Duration of response with CDK4/6 inhibitors
Track 26: Activity of abemaciclib in patients with brain metastases
Track 27: Predictors of benefit from CDK4/6 inhibitors
Track 28: Effects of site and extent of metastases on outcomes with CDK4/6 inhibitors
Track 29: Choice of CDK4/6 inhibitor based on symptomatology and disease burden
Track 30: Selection of first-line therapy for patients with ER-positive, HER2-negative breast cancer and extensive visceral metastases
Track 31: Role of chemotherapy as up-front treatment for patients with ER-positive, HER2-negative mBC
Track 32: Efficacy of endocrine therapy and/or CDK4/6 inhibitors in combination with chemotherapy or radiation therapy
Track 33: Activity of CDK4/6 inhibitors in the CNS

Module 5 Pathophysiology of class- and agent-specific toxicities and optimal management strategies

Track 34: Similarities and differences in the toxicity profiles of palbociclib, abemaciclib and ribociclib
Track 35: Monitoring and mitigation of toxicities associated with palbociclib and ribociclib
Track 36: Management of abemaciclib-associated diarrhea
Track 37: Potential drug interactions in patients receiving CDK4/6 inhibitors
Track 38: Selection of endocrine therapy for men with ER-positive, HER2-negative mBC
Track 39: Perspective on the efficacy of tamoxifen and CDK4/6 inhibitors for men with ER-positive, HER2-negative mBC

Module 6 Mechanisms of resistance to CDK4/6 inhibitors, treatment beyond disease progression and novel strategies with combinations

Track 40: Therapy for patients with ER-positive, HER2-negative mBC after disease progression on a CDK4/6 inhibitor; mechanisms of resistance to CDK4/6 inhibitors
Track 41: Potential role of CDK4/6 inhibitors for patients with HER2-positive mBC
Track 42: Rationale for combining HER2-targeted therapy and CDK4/6 inhibitors
Track 43: Therapeutic approach to disease progression on a CDK4/6 inhibitor
Track 44: Results of the Phase III SOLAR-1 trial: Alpelisib with fulvestrant for hormone receptor-positive, HER2-negative advanced breast cancer
Track 45: Activity and safety profile of PI3 kinase inhibitors
Track 46: Clinical experience with PI3 kinase inhibitors
Track 47: Perspective on the results of the SOLAR-1 study
 
CO-CHAIR
 
Sara M Tolaney, MD, MPH
Associate Director, Susan F Smith Center for Women’s Cancers
Director of Clinical Trials
Breast Oncology
Director of Breast Immunotherapy Clinical Research
Senior Physician
Breast Oncology Program
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts
 
FACULTY
 
Neelima Denduluri, MD
Associate Chair
US Oncology Breast Cancer Research Committee
Medical Oncologist
Virginia Cancer Specialists
Arlington, Virginia
 
Shom Goel, MBBS, PhD
Instructor in Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts
 
Erika Hamilton, MD
Director, Breast and Gynecologic Research Program
Sarah Cannon Research Institute
Nashville, Tennessee
 
Komal Jhaveri, MD
Assistant Attending
Breast Medicine and Early Drug
Development Services
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
 
Ruth M O’Regan, MD
Professor of Medicine
Chief
Division of Hematology/Oncology
University of Wisconsin
Carbone Cancer Center
Madison, Wisconsin
 
CHAIR AND MODERATOR
 
Neil Love, MD
Research To Practice
Miami, Florida